Sec Form 3 Filing - Rudnick Stanford @ Syneos Health, Inc. - 2023-03-31

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Rudnick Stanford 2. Issuer Name and Ticker or Trading Symbol Syneos Health, Inc. [ SYNH] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) See remarks (Last) (First) (Middle) C/O SYNEOS HEALTH, INC., 1030 SYNC ST 3. Date of Earliest Transaction (MM/DD/YY) 03/31/2023 (Street) MORRISVILLE, NC27560 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Class A Common Stock 31,518 ( 1 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy Class A Common Stock) $ 43.16 ( 2 ) 07/29/2025 Class A Common Stock 166 D Stock Option (Right to Buy Class A Common Stock) $ 42.88 ( 2 ) 01/19/2026 Class A Common Stock 537 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Rudnick Stanford C/O SYNEOS HEALTH, INC. 1030 SYNC ST MORRISVILLE, NC27560 See remarks Signatures /s/ Sara Epstein, Attorney-in-Fact 04/10/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Includes (i) 408 restricted stock units ("RSUs") that vest on April 18, 2023; (ii) 612 RSUs that vest on April 18, 2023; (iii) 704 RSUs that vest on May 16, 2023; (iv) 704 RSUs that vest on January 15, 2024; (v) 2,345 RSUs that vest on January 17, 2024; (vi) 610 RSUs that vest on January 18, 2024; (vii) 1,407 RSUs that vest on February 15, 2024; (viii) 217 RSUs that vest on February 16, 2024; (ix) 408 RSUs that vest on April 18, 2024; (x) 612 RSUs that vest on April 18, 2024; (xi) 2,112 RSUs that vest on May 16, 2024; (xii) 5,782 RSUs that vest on December 15, 2024; (xiii) 2,345 RSUs that vest on January 17, 2025; (xiv) 611 RSUs that vest on January 18, 2025; (xv) 1,407 RSUs that vest on February 15, 2025; (xvi) 408 RSUs that vest on April 18, 2025; (xvii) 612 RSUs that vest on April 18, 2025; (xviii) 2,346 RSUs that vest on January 17, 2026; (xix) 1,408 RSUs that vest on February 15, 2026, all subject to continued employment. ( 2 )The shares subject to this option are fully vested.

Remarks: Interim Chief Financial OfficerExhibit List: Exhibit 24 - Power of Attorney

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.